AB1119 GUSELKUMAB EFFICACY AND SAFETY ANALYSIS FOR PSA ACCORDING TO BASELINE CHARACTERISTICS AS GENDER, OBESITY OR PREVIOUS TREATMENT IN REAL LIFE AFTER 52 WEEKS | Publicación